CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine ...
Chimeric antigen receptor T-cell therapy conferred sustained benefit to individuals with high-risk smoldering multiple myeloma, according to phase 2 trial results. All patients who received a single ...
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...
There is new research happening at Roswell Park Comprehensive Cancer Center to see if CAR T-cell therapy that has worked for ...
Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to ...
CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...
A personalized CAR T-cell therapy has sent a patient with three life-threatening autoimmune diseases into remission for over a year, after conventional treatments failed. The case adds to mounting ...
A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...
Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...
Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...
Researchers are advancing in vivo CAR-T cell engineering, which generates therapeutic immune cells directly inside patients, bypassing complex lab manufacturing. This approach could broaden access, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results